Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer’s disease and mild cognitive impairment

• Published in: Molecular psychiatry 2018-03, Vol.23 (3), p.767-776
• Main Authors: Lu, R, Wang, J, Tao, R, Zhu, T, Guo, W, Sun, Y, Li, H, Gao, Y, Zhang, W, Fowler, C J, Li, Q, Chen, S, Wu, Z, Masters, C L, Zhong, C, Jing, N, Wang, Y
• Format: Article
• Language: English
• Subjects: 13; 13/1; 14/1; 14/63; 38/1; 38/39; 38/77; 631/378; 64/60; 692/53/2421; 82/1; 82/29; Aged; Aging; Alzheimer Disease - blood; Alzheimer Disease - genetics; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid beta-protein; Animals; Behavioral Sciences; Biological Psychology; Biomarkers - blood; Blood; Blood cells; Brain; Case-Control Studies; Cerebrospinal fluid; Cognitive ability; Cognitive Dysfunction - diagnosis; Cognitive Dysfunction - genetics; Cognitive Dysfunction - metabolism; Development and progression; Diagnosis; Female; Health aspects; HEK293 Cells; Humans; Impairment; Ion channels; Jurkat Cells; Male; Medicine; Medicine & Public Health; Messenger RNA; Mice; Middle Aged; Movement disorders; mRNA; Neurodegenerative diseases; Neuroimaging; Neurosciences; original-article; Parkinson's disease; Peripheral blood; Pharmacotherapy; Physiological aspects; Pluripotency; Psychiatry; RNA, Messenger - blood; RNA, Messenger - genetics; Stem cell transplantation; Stem cells; tau Proteins; Tissues; Transient receptor potential proteins; TRPC6 Cation Channel - blood; TRPC6 Cation Channel - genetics; TRPC6 Cation Channel - metabolism; β-Amyloid
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/mp.2017.136

Transient receptor potential canonical 6 (TRPC6) inhibits β-amyloid (Aβ) production. Hyperforin, the TRPC6 agonist, reduces Aβ levels and improves cognitive performance in Alzheimer’s disease (AD) models. However, it’s unknown whether TRPC6 expression is changed in AD patients. In this case–control study, we measured TRPC6 expression levels in the peripheral blood cells of four independent AD sets from five hospitals and one mild cognitive impairment (MCI) set from a local community (229 AD, 70 MCI, 40 Parkinson disease and 359 controls from China, total n =698) using quantitative real-time PCR assay. We found a specific reduction of TRPC6 mRNA levels in four AD sets and one MCI set. The median TRPC6 mRNA levels were lower in the following: (1) combined AD patients than in age-matched controls (0.78 vs 1.73, P